Lv7
5008 积分 2022-08-08 加入
The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak
9天前
已完结
Involvement of lysophosphatidic acid-LPA1-YAP signaling in healthy and pathological FAPs migration
9天前
已完结
Advances in novel therapeutics for idiopathic pulmonary fibrosis
9天前
已完结
Synthesis and evaluation of novel dimethylpyridazine derivatives as hedgehog signaling pathway inhibitors
11天前
已完结
Design, synthesis and biological evaluation of anthranilamide derivatives as potent SMO inhibitors
11天前
已完结
Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
11天前
已完结
Development of taladegib as a sonic hedgehog signaling pathway inhibitor
11天前
已完结
Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases
18天前
已完结
Mechanism of hepatobiliary toxicity of the LPA1 antagonist BMS-986020 developed to treat idiopathic pulmonary fibrosis: Contrasts with BMS-986234 and BMS-986278
21天前
已完结
Mechanism of hepatobiliary toxicity of the LPA1 antagonist BMS-986020 developed to treat idiopathic pulmonary fibrosis: Contrasts with BMS-986234 and BMS-986278
22天前
已完结
皖公网安备34019202002308
